JP6527661B2 - 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法 - Google Patents

突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法 Download PDF

Info

Publication number
JP6527661B2
JP6527661B2 JP2013216224A JP2013216224A JP6527661B2 JP 6527661 B2 JP6527661 B2 JP 6527661B2 JP 2013216224 A JP2013216224 A JP 2013216224A JP 2013216224 A JP2013216224 A JP 2013216224A JP 6527661 B2 JP6527661 B2 JP 6527661B2
Authority
JP
Japan
Prior art keywords
seq
difficile
toxin
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013216224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014083054A (ja
JP2014083054A5 (https=
Inventor
ウテ ジャンセン キャサリン
ウテ ジャンセン キャサリン
シビル アンダーソン アンナリーサ
シビル アンダーソン アンナリーサ
ジー．ケイ． ドナルド ロバート
ジー．ケイ． ドナルド ロバート
ジェームズ フリント マイケル
ジェームズ フリント マイケル
クマール カリアン ナレンダー
クマール カリアン ナレンダー
アーノルド ロトヴィン ジェイソン
アーノルド ロトヴィン ジェイソン
ケイ． シドゥー マニンンダー
ケイ． シドゥー マニンンダー
キース モラン ジャスティン
キース モラン ジャスティン
エドワード ラッペン マーク
エドワード ラッペン マーク
サン ウェイキアング
サン ウェイキアング
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2014083054A publication Critical patent/JP2014083054A/ja
Publication of JP2014083054A5 publication Critical patent/JP2014083054A5/ja
Application granted granted Critical
Publication of JP6527661B2 publication Critical patent/JP6527661B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013216224A 2012-10-21 2013-10-17 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法 Active JP6527661B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261716605P 2012-10-21 2012-10-21
US61/716,605 2012-10-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019090728A Division JP6871969B2 (ja) 2012-10-21 2019-05-13 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法

Publications (3)

Publication Number Publication Date
JP2014083054A JP2014083054A (ja) 2014-05-12
JP2014083054A5 JP2014083054A5 (https=) 2016-11-24
JP6527661B2 true JP6527661B2 (ja) 2019-06-05

Family

ID=49546596

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013216224A Active JP6527661B2 (ja) 2012-10-21 2013-10-17 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法
JP2019090728A Active JP6871969B2 (ja) 2012-10-21 2019-05-13 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法
JP2021069760A Active JP7208293B2 (ja) 2012-10-21 2021-04-16 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法
JP2023000594A Active JP7556987B2 (ja) 2012-10-21 2023-01-05 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019090728A Active JP6871969B2 (ja) 2012-10-21 2019-05-13 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法
JP2021069760A Active JP7208293B2 (ja) 2012-10-21 2021-04-16 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法
JP2023000594A Active JP7556987B2 (ja) 2012-10-21 2023-01-05 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法

Country Status (19)

Country Link
US (5) US10787652B2 (https=)
EP (2) EP2909307B1 (https=)
JP (4) JP6527661B2 (https=)
KR (5) KR101751822B1 (https=)
CN (2) CN104797706B (https=)
AU (5) AU2013333532C1 (https=)
BR (2) BR122016023101B1 (https=)
CA (2) CA3063892C (https=)
DK (1) DK2909307T3 (https=)
ES (1) ES2878551T3 (https=)
HR (1) HRP20211170T1 (https=)
HU (1) HUE055594T2 (https=)
IL (3) IL237792B (https=)
MX (2) MX369289B (https=)
PL (1) PL2909307T3 (https=)
PT (1) PT2909307T (https=)
RU (1) RU2630671C2 (https=)
SI (1) SI2909307T1 (https=)
WO (1) WO2014060898A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
CA2976976C (en) * 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
KR101723167B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
EP3344276B1 (en) * 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN106801077A (zh) * 2017-02-13 2017-06-06 江南大学 一种高效杀灭滴虫等医学原虫的细菌培养上清液的制备方法和及其利用
WO2019064115A1 (en) * 2017-09-28 2019-04-04 Pfizer Inc. COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE
EP3946444A1 (en) * 2019-04-01 2022-02-09 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California VACCINE COMPOSITION FOR CLOSTRIDIUM DIFFICILE
CN115697330A (zh) * 2020-05-06 2023-02-03 阿尔伯特·爱因斯坦医学院 通过抑制肠道损伤性细菌毒素TcdA和TcdB预防来自艰难梭菌感染的组织损伤的活性剂
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
JP2025509460A (ja) 2022-03-14 2025-04-11 ファイザー・インク アジュバントを生産するための方法
AU2023393199A1 (en) 2022-12-13 2025-05-29 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
TWI909678B (zh) 2023-09-13 2025-12-21 美商輝瑞股份有限公司 產製佐劑之方法
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4530833A (en) * 1982-09-13 1985-07-23 Wilkins Tracy D Toxins and antibodies of C. difficile
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
EP0154064A1 (en) * 1984-03-02 1985-09-11 Tracy Dale Wilkins Toxins and antibodies of C. difficile
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
WO1992018652A1 (en) 1991-04-22 1992-10-29 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
WO1994022476A1 (en) 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
EP0779819A1 (en) 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
NZ295998A (en) 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
JPH11510793A (ja) 1995-07-07 1999-09-21 オラバックス インク． 胃腸病に対する鼻腔内ワクチン接種
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
ATE272409T1 (de) 1996-09-30 2004-08-15 Univ Arkansas Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
JP2002541808A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
EP1278764A4 (en) 2000-05-04 2004-05-19 Harvard College CONNECTIONS AND METHODS FOR TREATING AND PREVENTING BACTERIAL INFECTIONS (11/14/01)
WO2003000719A2 (en) 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
EP1709170B1 (en) 2004-01-16 2018-02-21 Pfenex Inc. Expression of mammalian proteins in pseudomonas fluorescens
NZ530709A (en) * 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
DK2270045T3 (en) * 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
WO2006071877A2 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
ES2509872T3 (es) * 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
US20080206819A1 (en) 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
SI2124556T1 (sl) * 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
PL2198007T3 (pl) 2007-09-14 2018-03-30 Sanofi Pasteur Biologics, Llc Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile
WO2009132082A2 (en) 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US8206940B2 (en) 2008-05-15 2012-06-26 Tufts University Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression
EP2310045A1 (en) 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
EP2329029B1 (en) 2008-09-24 2016-06-08 Sanofi Pasteur Biologics, LLC Methods and compositions for increasing toxin production
US8444996B2 (en) * 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
UA105508C2 (uk) * 2008-12-03 2014-05-26 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання вакцини проти clostridium difficile
SI2759306T1 (sl) 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
GB0901001D0 (en) 2009-01-22 2009-03-04 Univ Nottingham Methods
AU2010215275B2 (en) 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
WO2011031568A2 (en) 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
WO2011068953A2 (en) 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
KR20130072201A (ko) * 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
US8765399B2 (en) * 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
WO2012028418A1 (en) * 2010-09-02 2012-03-08 Novacem Limited Integrated process for producing compositions containing magnesium
PL2753352T5 (pl) * 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
EP2638063A4 (en) 2010-11-12 2014-04-23 Reflexion Pharmaceuticals Inc GB1 PEPTIDE LIBRARIES AND CONNECTIONS AND SCREENING METHOD THEREFOR
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
HUE037126T2 (hu) * 2011-05-27 2018-08-28 Glaxosmithkline Biologicals Sa Immunogén készítmény
US9770500B2 (en) 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
US20150071958A1 (en) * 2011-11-30 2015-03-12 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CA2882620A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
WO2014086787A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US20160045586A1 (en) * 2013-03-15 2016-02-18 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
US20170165375A1 (en) 2013-04-02 2017-06-15 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
WO2015061529A1 (en) * 2013-10-23 2015-04-30 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3377613A1 (en) 2015-11-17 2018-09-26 Pfizer Inc Media and fermentation methods for producing polysaccharides in bacterial cell culture
MA44252A (fr) * 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
MX2019010948A (es) 2017-03-15 2020-01-09 Novavax Inc Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.
US10577665B2 (en) 2017-09-05 2020-03-03 Mcmaster University Aptamers for clostridium difficile detection
WO2019064115A1 (en) 2017-09-28 2019-04-04 Pfizer Inc. COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE
EP3946444A1 (en) 2019-04-01 2022-02-09 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Also Published As

Publication number Publication date
AU2017201193A1 (en) 2017-03-16
CA2887891A1 (en) 2014-04-24
JP2023036952A (ja) 2023-03-14
US20250002875A1 (en) 2025-01-02
IL284582B (en) 2022-12-01
AU2017201193C1 (en) 2019-10-24
US20190112584A1 (en) 2019-04-18
US10787652B2 (en) 2020-09-29
CA3063892C (en) 2023-05-09
IL237792B (en) 2021-03-25
MX2015004986A (es) 2015-07-17
US10982198B2 (en) 2021-04-20
KR101990272B1 (ko) 2019-06-17
HUE055594T2 (hu) 2021-12-28
AU2017201193B2 (en) 2019-02-07
HRP20211170T1 (hr) 2021-11-12
BR112015008844A8 (pt) 2018-04-03
KR102169216B1 (ko) 2020-10-22
PT2909307T (pt) 2021-07-14
HK1254448A1 (zh) 2019-07-19
IL284582A (en) 2021-08-31
SI2909307T1 (sl) 2021-08-31
ES2878551T3 (es) 2021-11-19
EP3912990A1 (en) 2021-11-24
JP2014083054A (ja) 2014-05-12
AU2019203159B2 (en) 2020-05-07
KR101751822B1 (ko) 2017-06-28
IL271064A (en) 2020-01-30
IL271064B (en) 2021-07-29
KR20190008988A (ko) 2019-01-25
BR112015008844A2 (pt) 2017-11-21
KR20150056843A (ko) 2015-05-27
RU2630671C2 (ru) 2017-09-11
AU2013333532B2 (en) 2016-11-24
US20200165582A1 (en) 2020-05-28
AU2020203423A1 (en) 2020-06-11
MX379863B (es) 2025-03-11
US20150291940A1 (en) 2015-10-15
WO2014060898A3 (en) 2014-06-12
AU2013333532C1 (en) 2019-10-24
BR122016023101A2 (pt) 2019-08-27
AU2019203159A1 (en) 2019-05-30
AU2013333532A1 (en) 2015-04-02
CN104797706B (zh) 2020-05-26
IL237792A0 (en) 2015-05-31
US11952597B2 (en) 2024-04-09
JP2019150045A (ja) 2019-09-12
JP6871969B2 (ja) 2021-05-19
JP7208293B2 (ja) 2023-01-18
HK1212385A1 (en) 2016-06-10
JP7556987B2 (ja) 2024-09-26
MX2019013075A (es) 2019-12-16
AU2021277590A1 (en) 2021-12-23
BR122016023101B1 (pt) 2022-03-22
IL284582B2 (en) 2023-04-01
EP2909307B1 (en) 2021-05-26
CA2887891C (en) 2023-03-07
MX369289B (es) 2019-11-04
CA3063892A1 (en) 2014-04-24
KR102078517B1 (ko) 2020-02-18
CN104797706A (zh) 2015-07-22
KR20170077263A (ko) 2017-07-05
PL2909307T3 (pl) 2022-11-07
KR20190069604A (ko) 2019-06-19
KR101940939B1 (ko) 2019-01-21
KR20200017552A (ko) 2020-02-18
WO2014060898A2 (en) 2014-04-24
JP2021119775A (ja) 2021-08-19
DK2909307T3 (da) 2021-07-05
EP2909307A2 (en) 2015-08-26
CN108004286A (zh) 2018-05-08
US11208633B2 (en) 2021-12-28
CN108004286B (zh) 2022-03-08
BR112015008844B1 (pt) 2022-03-22
RU2015112079A (ru) 2016-12-10
US20210024903A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
JP7208293B2 (ja) 突然変異クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）毒素に関する組成物および方法
CA2832712C (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
HK40035897A (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
HK1254448B (en) Compositions and methods relating to a mutant clostridium difficile toxin
HK1212385B (zh) 涉及突变型艰难梭菌毒素的组合物和方法
HK1195325B (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190513

R150 Certificate of patent or registration of utility model

Ref document number: 6527661

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250